Abstract:In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics especially peptides and proteins. In the intervening period, analysis of the preclinical and clinical trial failures of many purported platform technologies has led to reflection on the true status of the field and reigning in of expectations. Oral formulations of semaglutide, octreotide, and salmon calcitonin have completed Phase III trials, with oral semaglutide being approved by the FDA in 2019. The progress made with oral peptide formulations based on traditional permeation enhancers is against a background of low and variable oral bioavailability values of ~1%, leading to a current perception that only potent peptides with a viable cost of synthesis can be realistically considered. Desirable features of candidates should include a large therapeutic index, some stability in the GI tract, a long elimination half-life, and a relatively low clearance rate. Administration in nanoparticle formats have largely disappointed, with few prototypes reaching clinical trials: insufficient particle loading, lack of controlled release, low epithelial particle uptake, and lack of scalable synthesis being the main reasons for discontinuation. Disruptive technologies based on engineered devices promise improvements, but scale-up and toxicology aspects are issues to address. In parallel, medicinal chemists are synthesizing stable hydrophobic macrocyclic candidate peptides of lower molecular weight and with potential for greater oral bioavailability than linear peptides, but perhaps without the same requirement for elaborate drug delivery systems. In summary, while there have been advances in understanding the limitations of peptides for oral delivery, low membrane permeability, metabolism, and high clearance rates continue to hamper progress.

Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Recent Advances in Oral and Transdermal Protein Delivery Systems

Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals

Lipid-Based Nanoparticles as Oral Drug Delivery Systems: Overcoming Poor Gastrointestinal Absorption and Enhancing Bioavailability of Peptide and Protein Therapeutics

Challenges and opportunities in delivering oral peptides and proteins

Towards the Development of Orally Available Peptide Therapeutics.

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Adapting Liposomes for Oral Drug Delivery

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Nanoparticles: Oral Delivery for Protein and Peptide Drugs

Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs

Oral Delivery of Protein Drugs via Lysine Polymer‐Based Nanoparticle Platforms

Advances in Lipid-Based Drug Delivery: Enhancing Efficiency for Hydrophobic Drugs

Biopolymer-liposome hybrid systems for controlled delivery of bioactive compounds: Recent advances

Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules

A Perspective of Engineered Lipids and Liposomes: Chemical Design and Functional Application Based on Therapeutic Safety

Polymeric Micelles, a Promising Drug Delivery System to Enhance Bioavailability of Poorly Water-Soluble Drugs.

Enhanced oral bioavailability from food protein nanoparticles: A mini review